ABSTRACT
Biological drugs make up one of the fastest-growing sectors of the pharmaceutical and biotechnology industry (IMS, 2010). For example, in 2010, spending on global biologics totaled about $138 billion. The spending of biosimilars has grown rapidly in the past few years. It is expected that spending on biologics will roar to over $200 billion beyond 2015 (see, e.g., Figure 8.1). This has given the pharmaceutical and biotechnology industry the opportunity to develop biosimilars when the innovative biologics go off patent protection.
